Navigation Links
Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
Date:6/18/2009

DOYLESTOWN, Pa., June 18 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that Ted Karkus, Chairman of the Board of The Quigley Corporation, has been appointed Interim Chief Executive Officer by the Board of Directors of the Company. Mr. Karkus will serve in this role effective June 18, 2009 and will be compensated at a rate of $5,000 per week for his services.

Mr. Karkus will temporarily assume the duties and responsibilities of Interim Chief Executive Officer while the Board of Directors reviews the Company's operations and staffing at the executive management level.

This appointment may be terminated by the Board of Directors at any time.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:

    Ted Karkus                  Media                   Investor Relations
    Chairman of the Board, CEO  Karen Pineman           Carl Hymans
    The Quigley Corporation     G.S. Schwartz & Co.     G.S. Schwartz & Co.
    (516) 569-9999              212.725.4500            212.725.4500
                                kpineman@schwartz.com   carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
2. Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
3. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
4. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
5. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
6. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
7. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
8. Netsmarts Haines Reappointed to CCHIT Behavioral Health Work Group
9. Antiabortion Advocate Appointed to Senior Position at HHS
10. President of PRN Funding Appointed to Factoring Association Advisory Board
11. Dr. James Hevezi Appointed as Chief Physicist for CyberKnife Center of Miami
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... ... firm in Allegheny County that offers services to communities throughout the greater Pittsburgh ... in a charity drive to provide adaptive bicycles for differently-abled children. , Variety ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, ... Advocacy Award in recognition of her extraordinary contributions to the field of patient ... Beryl Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... ... 21, 2017 , ... Crossover Symmetry , an evidence ... active lifestyle company that provides Human Performance Training and education to tactical athletes. ... responders, military officers and others in service through the development and conditioning of ...
(Date:4/21/2017)... ... 2017 , ... Airway Management, the medical device manufacturer of ... and well renowned Asian distributor, Discovery Sleep. The agreement involves the ... and will stabilize and strengthen Airway’s presence with a dedicated, reputable medical device ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... candidates to serve on its Accreditation and Standards Committees to support the ... is improving image quality and reducing patient radiation dose,” reports Eliot Siegel, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  New research provides evidence that ... Parkinson,s, according to a study released today that will be ... Meeting in Boston , April 22 ... the treatment of Parkinson,s disease, the oral drug levodopa has ... and longevity. But as the disease progresses, the effects of ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... 2017 Research and Markets has announced the ... to their offering. ... arthroscopy devices market to grow at a CAGR of 6.35% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Medicine Technology: